✦ LIBER ✦

PHP52 A RANDOMIZED, OPEN-LABEL PREFERENCE STUDY OF GENGRAF® COMPARED TO NEORAL® IN STABLE SOLID-ORGAN TRANSPLANT RECIPIENTS

✍ Scribed by S Steinberg; R Venuto; KC Kuruvila; D Taylor; MS Anil Kumar; MR First; R Greco; TI Boodhoo; A Singh; T Ashraf; AJ Japour; J Ryan

Book ID: 119591840
Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 62 KB
Volume: 5
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)60911-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, open-label study to evalua

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients

✍ Gary L. Davis; David R. Nelson; Norah Terrault; Timothy L. Pruett; Thomas D. Sch 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Collaborative Antiviral Study Group Chronic hepatitis C is the most common indication for liver transplantation, but viral recurrence is universal and progressive graft injury occurs in most recipients. Our aim was to assess the safety, pharmacokinetics (PK), and antiviral effects of high doses

A 12-month, multicenter, randomized, ada

A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2 hour monitoring of neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction

✍ M Cantarovich; H Ross; J Arizon; J Orus; L Straatman; J Howlett; E Lage; M Cresp 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 75 KB

A 12-month, multicenter, randomized, ada

A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2-hr monitoring of Neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction: 6-month outcomes

✍ H. Ross; M. Cantarovich; J. Arizon; J. Orus; L. Straatman; J. Howlett; E. Lage; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 66 KB

249: A Randomized, Open-Label Study To C

249: A Randomized, Open-Label Study To Compare the Safety and Efficacy of Conversion From a Calcineurin Inhibitor (CNI) to Sirolimus Versus Continued Use of a CNI in Cardiac Transplant Recipients with Mild to Moderate Renal Insufficiency

✍ A. Zuckermann; A. Keogh; M.G. Crespo-Leiro; D. Mancini; F. Gonzalez-Vilchez; L. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 65 KB